Sanofi confirms deal to buy Bioverativ for $11.6 billion
January 22, 2018 at 01:22 AM EST
PARIS (Reuters) - French healthcare group Sanofi has agreed to buy U.S. peer Bioverativ for $11.6 billion, in a deal which Sanofi said would boost its earnings and strengthen its presence in the field of treatment for rare diseases.